Westmount Partners LLC Lowers Stock Holdings in Illumina, Inc. $ILMN

Westmount Partners LLC reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 12.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,119 shares of the life sciences company’s stock after selling 4,984 shares during the quarter. Illumina makes up approximately 1.1% of Westmount Partners LLC’s portfolio, making the stock its 18th biggest position. Westmount Partners LLC’s holdings in Illumina were worth $4,329,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of ILMN. Elyxium Wealth LLC acquired a new stake in shares of Illumina during the fourth quarter worth about $25,000. Board of the Pension Protection Fund purchased a new position in shares of Illumina in the fourth quarter valued at approximately $26,000. Creative Capital Management Investments LLC grew its holdings in shares of Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina in the fourth quarter valued at approximately $26,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in Illumina during the 4th quarter worth approximately $26,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Barclays increased their target price on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a report on Friday, May 1st. Guggenheim boosted their price target on shares of Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Citigroup increased their price objective on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Finally, Wall Street Zen lowered Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $142.12.

Insiders Place Their Bets

In related news, insider Scott M. Davies sold 615 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $98,400.00. Following the transaction, the insider owned 21,568 shares of the company’s stock, valued at $3,450,880. This represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,003,154 shares of company stock worth $155,600,208. 2.90% of the stock is currently owned by insiders.

Illumina Price Performance

ILMN stock opened at $161.93 on Friday. The company’s 50 day moving average price is $145.20 and its 200 day moving average price is $136.16. The firm has a market capitalization of $24.50 billion, a price-to-earnings ratio of 29.44, a PEG ratio of 3.03 and a beta of 1.50. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $177.22. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the firm earned $0.97 earnings per share. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 5.21 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.